We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

National Institutes of Health Funds $13.7 Million for Texas Tuberculosis Study

National Institutes of Health Funds $13.7 Million for Texas Tuberculosis Study

National Institutes of Health Funds $13.7 Million for Texas Tuberculosis Study

National Institutes of Health Funds $13.7 Million for Texas Tuberculosis Study

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "National Institutes of Health Funds $13.7 Million for Texas Tuberculosis Study"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The National Institute of Health has granted $13.7 million for a five-year tuberculosis research project, headed by Dr. Jim Sacchettini and a team of scientists with the Texas Agricultural Experiment Station.

Sacchettini said the team will examine three-dimensional structures of a large number of proteins in the TB genome. Their goal is to discover new drugs to treat the disease.

He said the project is the only large-scale structural biology project in the NIH program that will focus on a single organism.

The team will collaborate on the grant with researchers from the University of California-Los Angeles, University of California-Berkeley and Los Alamos National Laboratories

"We will work on the proteins (from Mycobacteria TB) which, as drug targets, have the potential of reducing to just a few weeks what is now 6-9 months of chemotherapy," Sacchettini said.

He explained that while TB is curable, most people inflicted with the disease do not finish their treatment because the time required is lengthy.

The bacteria that causes the disease, Mycobacterium TB, can evade the human immune system and drug therapy for years by living in a persistent and dormant state.

"When they awake, the infection can reactivate in the person," he said.

"Most people who start therapy never finish. In some of the most infected countries in the world, it's often difficult to get medicine over the period of several months which is required to cure the disease," he said.

"Our main focus is to look at the structures of targets that, if inactivated by a drug, will kill the bacteria quickly," he explained.

Sacchettini said, "The team created a technology pipeline where we can rapidly take any drug target to a 3-D structure in atomic resolution."

"In many cases a structure can be solved in just a few weeks. Then we can look for potential drugs using 'grid virtual screening'. That can dramatically improve the drug development process."

Grid virtual screening, he explained, is the use of some 1,000 computers on the Texas A&M University campus to dock drug-like molecules into a protein structure to see if they have potential for drug development.

"We use the computers when they are idle, for example, at night, on weekends and holidays when they are not in use by day workers," he said.

This allows scientists to condense what would have been a couple of years of work into a couple of days, he explained.

"We go from the genetics and microbiology to identify targets, then to the pipeline of researchers in the worldwide consortium to help solve the 3-D structure, then to computerized screening to identify potential drugs," he said.

"Under ideal conditions the whole process can be completed in just a few weeks," he added.

"New drugs are always far away. It takes a long time to come out with a new drug," he said.

"Even with these faster methods of research, it still likely will be at least seven years before we have a compound in the testing stage. But without these new technologies, it would have taken at least twice that."